Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine versus sulfadoxine-pyrimethamine for uncomplicated malaria in eastern Terai, Nepal
ACTRN12605000551695Phase 4Recruiting
- Sponsor
- RTI International
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of artemether + lumefantrine and sulfadoxine + pyrimethamine in malaria and Malaria (2 arms), sponsored by RTI International. Primary endpoint: 28-day parasitological cure rate. Started Aug 2005; status: recruiting.
02
Drugs
artemether + lumefantrinesulfadoxine + pyrimethamine
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on ACTRN12605000551695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000551695.